A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis

Pediatric Pulmonology

Volumn 33, Issue 2, 2002, Pages 90-98

  McCarty, Nael A ^a,g   Standaert, Thomas A ^b   Teresi, Mary ^c   Tuthill, Cynthia ^d   Launspach, Janice ^c   Kelley, Thomas J ^e   Milgram, Laura J H ^e   Hilliard, Kathleen A ^e   Regelmann, Warren E ^f   Weatherly, Mark R ^a   Aitken, Moira L ^b   Konstan, Michael W ^e   Ahrens, Richard C ^c  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d SciClone Pharmaceuticals Inc   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^g GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Clinical trials; Cystic fibrosis; Genotype specific therapy; Nasal potential difference; Protein repair therapy; Sweat chloride measurement

Indexed keywords

8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; PLACEBO;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENETIC DISORDER; GENOTYPE; HUMAN; LUNG FUNCTION TEST; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; TREATMENT OUTCOME; VERTIGO;

ADOLESCENT; ADULT; CHLORIDES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MEMBRANE POTENTIALS; MUTATION, MISSENSE; NASAL MUCOSA; PEPTIDE FRAGMENTS; RECEPTORS, PURINERGIC P1; REGRESSION ANALYSIS; RESEARCH DESIGN; SWEAT; TREATMENT OUTCOME; XANTHINES;

EID: 0036161237     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.10041     Document Type: Article

References (28)

1. Cystic fibrosis
2. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA
3. Physiological basis of cystic fibrosis: A historical perspective
4. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis
5. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis
6. Altered chloride ion channel kinetics associated with (delta)F508 cystic fibrosis mutation
7. Chloride conductance expressed by (delta)F508 and other mutant CFTRs in Xenopus oocytes
8. Delta F508-CFTR channels: Kinetics, activation by forskolin, and potentiation by xanthines
9. Cystic fibrosis transmembrane conductance regulator activation by cAMP-independent mechanisms
10. Deletion of phenyl-alanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels
11. Future pharmacological treatment of cystic fibrosis
12. Cystic fibrosis: Molecular biology and therapeutic implications
13. 1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells
14. A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane conductance regulator delta F508 mutation
15. Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, ginistein and CPX
16. Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX)
17. Activation of wild-type and ΔF508-CFTR by phosphodiesterase inhibitors through cAMP-dependent and -independent mechanisms
18. CPX, a selective A1-adenosine-receptor antagonist, regulates intracellular pH in cystic fibrosis cells
19. No evidence for direct activation of the cystic fibrosis transmembrane conductance regulator by 8-cyclopentyl-1,3-dipropylxanthine
20. Stimulation by alkylxanthines of chloride efflux in CFPAC-1 cells does not involve A1 adenosine receptors
21. 8-Cyclopentyl-1,3-dipropylxanthine and other xanthines differentially bind to the wild-type and delta F508 first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator
22. Cystic fibrosis and the use of pharmacogenomics to determine surrogate endpoints for drug discovery
23. Nasal potential difference measurements in ΔF508 CF patients with mild lung disease
24. Safety of a phase I double-blind placebo-controlled dose escalation trial of oral CPX in adult CF patients
25. Multicenter phase I trial of CPX in adult patients with mild CF: Results of nasal potential difference measurements
26. Pharmacokinetics of CPX (8-cyclopentyl-1,3-dipropylxanthine) in adults with cystic fibrosis
27. Use of the nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis
28. In vivo potential difference: Techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis